OverviewSuggest Edit

Sorrento Therapeutics is a biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases. The Company's lead programs consist of four Phase III BioSimilar/BioBetter antibodies. It is also advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).
TypePublic
Founded2006
HQSan Diego, US
Websitesorrentotherapeutics.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Dec 2018)382(+136%)
Job Openings26
Revenue (FY, 2018)$21.2 M(-86%)
Share Price (Jun 2019)$3 (+3%)

Key People/Management at Sorrento Therapeutics

Henry Ji

Henry Ji

Chairman, President and Chief Executive Officer
Jerome Zeldis

Jerome Zeldis

Chief Medical Officer
George Ng

George Ng

EVP, Chief Administrative and Legal Officer
Dean Ferrigno

Dean Ferrigno

Vice President, Finance
Show more

Sorrento Therapeutics Office Locations

Sorrento Therapeutics has an office in San Diego
San Diego, US (HQ)
4955 Directors Pl
Show all (1)

Sorrento Therapeutics Financials and Metrics

Sorrento Therapeutics Revenue

Sorrento Therapeutics's revenue was reported to be $21.19 m in FY, 2018
USD

Revenue (Q1, 2019)

6.1m

Gross profit (Q1, 2019)

3.8m

Gross profit margin (Q1, 2019), %

62.4%

Net income (Q1, 2019)

(146.5m)

EBIT (Q1, 2019)

(123.2m)

Market capitalization (10-Jun-2019)

368.9m

Closing stock price (10-Jun-2019)

3.0

Cash (31-Mar-2019)

91.0m
Sorrento Therapeutics's current market capitalization is $368.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

460.1k3.8m4.6m8.2m151.9m21.2m

Revenue growth, %

731%20%78%

Cost of goods sold

2.0m811.0k3.9m7.1m

Gross profit

2.6m7.3m147.9m14.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

83.8k976.0k775.0k1.3m977.0k1.2m1.1m988.0k902.0k2.2m4.9m4.7m121.9m6.2m3.9m4.1m6.1m

Cost of goods sold

527.0k314.0k604.0k359.0k295.0k418.0k1.1m816.0k1.1m1.3m1.2m2.2m2.3m

Gross profit

749.0k859.0k499.0k629.0k607.0k1.8m3.8m3.8m120.8m4.9m2.7m1.9m3.8m

Gross profit Margin, %

59%73%45%64%67%81%78%83%99%79%69%47%62%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

31.7m71.9m39.0m82.4m20.4m158.7m

Current Assets

32.6m73.9m141.0m89.7m29.7m179.6m

PP&E

2.4m2.3m7.2m12.7m19.3m24.4m

Goodwill

24.0m24.0m20.6m41.5m38.3m38.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

6.4m29.9m50.2m44.3m60.5m51.7m59.1m20.8m98.2m66.5m33.9m53.7m38.3m24.3m46.8m135.4m91.0m

Inventories

4.6m

Current Assets

6.9m31.2m51.4m45.8m62.2m53.8m124.8m71.7m146.3m71.8m42.1m60.6m44.7m36.6m54.7m145.2m118.6m

PP&E

1.7m2.4m2.3m2.4m2.5m2.8m3.8m7.4m9.2m10.1m17.0m18.0m19.0m19.5m19.9m21.5m28.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(21.9m)(34.7m)(50.1m)(63.9m)11.1m(212.5m)

Depreciation and Amortization

1.3m3.2m2.4m2.9m7.1m9.1m

Inventories

(3.2m)

Accounts Payable

878.6k(497.0k)(2.7m)3.7m1.6m3.6m
USDY, 2019

Financial Leverage

5.2 x
Show all financial metrics

Sorrento Therapeutics Online and Social Media Presence

Embed Graph

Sorrento Therapeutics News and Updates

Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced the pricing of its pub…

Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca).

SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB Riley Investor Conference and meeting with individual investors.

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and p…

The Wall Street Journal: Sorrento Therapeutics sues billionaire Soon-Shiong over development of cancer drug

Sorrento Therapeutics Inc. alleges billionaire Patrick Soon-Shiong and one of his companies stopped development of an experimental cancer drug because its success would hurt sales of a rival drug sold by Celgene Corp. that Dr. Soon-Shiong invented, according to a civil complaint filed Wednesday in …

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

Semnur’s SP102, addressing multi-billion dollar unmet market needs, in Pivotal Phase 3 Trial with Fast Track Status from the FDA
Show more

Sorrento Therapeutics Frequently Asked Questions

  • When was Sorrento Therapeutics founded?

    Sorrento Therapeutics was founded in 2006.

  • Who are Sorrento Therapeutics key executives?

    Sorrento Therapeutics's key executives are Henry Ji, Jerome Zeldis and George Ng.

  • How many employees does Sorrento Therapeutics have?

    Sorrento Therapeutics has 382 employees.

  • What is Sorrento Therapeutics revenue?

    Latest Sorrento Therapeutics annual revenue is $21.2 m.

  • What is Sorrento Therapeutics revenue per employee?

    Latest Sorrento Therapeutics revenue per employee is $55.5 k.

  • Who are Sorrento Therapeutics competitors?

    Competitors of Sorrento Therapeutics include Celyad, Alnylam Pharmaceuticals and Pernix Therapeutics.

  • Where is Sorrento Therapeutics headquarters?

    Sorrento Therapeutics headquarters is located at 4955 Directors Pl, San Diego.

  • Where are Sorrento Therapeutics offices?

    Sorrento Therapeutics has an office in San Diego.

  • How many offices does Sorrento Therapeutics have?

    Sorrento Therapeutics has 1 office.